Fauci: ‘clear-cut’ evidence potential Covid-19 drug remdesivir works
Gilead Sciences reported that preliminary results from a drug study for coronavirus showed that at least 50% of patients who received a 5-day dose of the antiviral drug remdesivir improved, and more than half were discharged from the hospital within two weeks..
The company also said another study by the National Institute of Allergy and Infectious Diseases achieved its primary goal. However, she did not provide further details..
The clinical study involved 397 patients with severe cases of Covid-19. The study was non-comparative, meaning it did not evaluate the drug versus a control group of patients who did not receive the drug..
The study tracked two groups of patients who were hospitalized with Covid-19. One group received a 5-day course of remdesivir treatment and the other group took the drug for 10 days. The researchers said that more than half of the patients in both groups were discharged from the hospital within 14 days. They said that 64.5% of the patients who received the shorter course of treatment were discharged, compared with 53.8% of the group who received treatment within 10 days..
«These data are encouraging as they indicate that patients who received the shorter 5-day course of remdesivir experienced the same clinical improvement as patients who received the 10-day course of treatment.», – He speaks Aruna subramanian, research supervisor.
According to data compiled by Johns Hopkins University, there are no proven treatments for Covid-19, which has infected more than 3 million people worldwide and is responsible for at least 217,569 deaths to date. U.S. health officials say it will take at least 12-18 months to make a vaccine to prevent the disease, making finding an effective drug treatment even more important anytime soon..
A number of studies are currently underway that are testing Gilead’s remdesivir to determine its effectiveness in preventing coronavirus replication..
Remdesivir has shown some encouraging results in the treatment of SARS and MERS (Middle East Respiratory Syndrome), which are also caused by coronaviruses. Several health authorities in the United States, China and other parts of the world are using remdesivir, which has been tested as a possible treatment for the Ebola outbreak, in the hopes that the drug could shorten the duration of the damaging effects of Covid-19 in patients..
In recent weeks, Gilead shares have been able to "swing", since investors were betting "behind" and "against" on the development of a treatment for coronavirus.
Earlier this month, Gilead surged after one of its clinical trials revealed details that showed promising results in the treatment of the disease. The University of Chicago found that Covid-19 patients had «quick recovery from fever and respiratory symptoms» and were discharged in less than a week, according to STAT News.
The company’s shares fell last week after numerous reports, citing a draft document that was accidentally released by the World Health Organization, said the drug does not improve the condition of patients with Covid-19 disease and does not reduce the presence of the virus in the blood during clinical tests carried out in China.
At the moment, Gilead shares are up more than 5% and are trading at around $ 83 per share..